Sunfox Gets $7M to Take ECG Heart Tests Across India to Villages

Dehradun-based medtech startup Sunfox Technologies has raised $7 Mn (~₹67 Cr) in a Series A round led by stock market investor Ashish Kacholia, along with Lashit Sanghvi, Alchemy Capital and 3one4 Capital.

What stands out here is the backer mix this isn't a typical VC-led healthtech round. It's anchored by individual marquee investors known more for public markets than early-stage medtech, a signal that Sunfox's traction has crossed into "safe enough bet" territory.

That traction is real: Sunfox's ECG platform Spandan already screens roughly 5 million patients a year a scale most Series A medtech startups in India haven't come close to touching.

The Details

• Round size$7 Mn (~₹67 Cr), Series A
• Lead investors: Ashish Kacholia, Lashit Sanghvi, Alchemy Capital, 3one4 Capital
• Previous round: ₹15 Cr (~$1.8 Mn) led by Venture Catalysts
• Implied jump: Roughly 3.9x the size of its last raise
• Valuation: Not disclosed
• Deployment so far: ~60,000 Spandan devices across India, reaching 20,000+ villages

A Smartphone That Reads Your Heart

Spandan is a portable, 12-lead ECG device that connects to a smartphone, letting users check for arrhythmia or a suspected heart attack outside a hospital.

Results don't stop at the device they're reviewed remotely by doctors, round the clock.

This matters because cardiac emergencies are time-sensitive, and most of rural India sits far from a cardiologist. Spandan is built to shrink that distance to a phone screen.

The company already holds regulatory approvals in India, Ghana, and Kenya, among other markets groundwork that makes its next move look less like ambition and more like execution already in motion.

Chasing Clearances in the US and Europe

The fresh capital is earmarked for scaling Spandan across India, growing the team, and investing in R&D, clinical evidence and engineering.

But the more telling line item is international: Sunfox plans to build out regulatory, distribution and commercial capabilities in the US, Europe and Africa.

Medical device regulatory clearance in the US (FDA) or Europe (CE-MDR) is notoriously slow and expensive often 18-24 months and a meaningful chunk of a Series A on its own. Budgeting for it this early signals Sunfox sees India scale as already proven, and global markets as the next real growth lever.

What the Numbers Don't Tell You

A 3.9x jump in round size without a disclosed valuation is a pattern worth sitting with it usually means either the company doesn't want the market pricing its global ambitions yet, or the valuation jump itself wasn't dramatic enough to publicize. Either reading is plausible here.

The bigger unknown is device economics: 60,000 devices deployed is a strong distribution number, but Sunfox hasn't shared how many are active, paid subscriptions versus one-time hardware sales. In remote diagnostics, recurring usage not device count is what actually proves the model works.

The Bottom Line

Sunfox has built real reach in rural India. Whether that reach survives the jump to FDA paperwork and European regulators is the story worth following next.